CHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug discovery using its proprietary DragonFold AI technology
Retrieved on:
Thursday, June 9, 2022
Odyssey, MSD, Sanofi, Google, Company, Biology, Board of directors, Vertex Pharmaceuticals, Biotechnology, Central Executive Committee (PAP), 3D, Deep learning, Winfield F. Prime, CEO, University of Washington, IFM Therapeutics, Executive Committee, Senior, Therapy, University, Drug discovery, Wiley Prize, Machine learning, Institutional Venture Partners, Scorpion, Intellia Therapeutics, Patient, Doctor of Philosophy, Khosla Ventures, Technology, Gilead Sciences, Board, General Catalyst, DeepMind, Medicine, Y Combinator, World of A Song of Ice and Fire, Axial, Institute, Entropy, Cancer, Protein, Fine chemical, Pharmaceutical industry, Medical device, Medical imaging, Management, AI, Pfizer
CHARM Therapeutics has been created to combine these breakthroughs in 3D deep-learning with excellence in drug discovery and development, said Gary D. Glick Ph.D., Executive Chair of CHARM Therapeutics.
Key Points:
- CHARM Therapeutics has been created to combine these breakthroughs in 3D deep-learning with excellence in drug discovery and development, said Gary D. Glick Ph.D., Executive Chair of CHARM Therapeutics.
- We are advancing this technology and its application to the hit discovery, hit-to-lead and lead optimization processes of small molecule drug discovery.
- The Company is Chaired by Gary Glick, founder of IFM Therapeutics, Scorpion Therapeutics and Odyssey Therapeutics.
- London-based CHARM Therapeutics has raised $50 million to date and is building an interdisciplinary and entrepreneurial team, combining leaders from the fields of AI and biotechnology.